Complicated UTI treatment market set to top $12.7B by 2030
The global market for complicated urinary tract infection treatment is projected to rise from $9.44 billion in 2025 to $10.04 billion in 2026, with North America leading and Asia-Pacific growing fastest. The forecast points to rising chronic kidney disease, antibiotic resistance and more hospital-based care as major demand drivers.
Why it matters: - Complicated urinary tract infections are harder to treat than routine UTIs because patients often have underlying conditions, resistant bacteria or catheter-related infections. - The market’s growth reflects higher demand for specialized antibiotics, better diagnostics and more advanced infection management in hospitals and outpatient settings. - Rising chronic kidney disease cases make effective treatment more important because severe UTIs can worsen kidney damage and increase hospitalizations.
What happened: - The Business Research Company released its Complicated Urinary Tract Infection Treatment Global Market Report 2026 on November 19, 2026. - The report estimates the market at $9.44 billion in 2025 and $10.04 billion in 2026. - The report forecasts the market to reach $12.74 billion by 2030, implying a 6.1% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period.
The details: - The 2025-to-2026 growth rate is 6.4%. - Key growth drivers include more catheter-associated infections, rising antibiotic resistance, an aging global population, expanding hospital infrastructure and improved diagnosis of chronic urinary disorders. - Longer-term demand is expected to be supported by new antibiotics, more immunocompromised patients, wider use of outpatient infusion therapies, higher healthcare spending and better pathogen detection technologies. - The report flags emerging trends including stronger empiric therapy strategies, broader use of broad-spectrum antibiotics, higher hospitalization rates for complicated UTIs, more combination drug therapy and expansion of hospital pharmacy services. - Complicated UTI treatment uses targeted antibiotic regimens and supportive therapies to address infections complicated by structural abnormalities, immune deficiencies or catheter use. - Chronic kidney disease is a major growth driver because its prevalence is rising alongside diabetes, hypertension, obesity and smoking. - The Australian Institute of Health and Welfare reported in June 2024 that chronic kidney disease accounted for 1.1% of Australia’s total disease burden in 2023. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - A free sample report is available. - The full market report is also available.
Between the lines: - The forecast suggests the market is being pulled by both greater disease burden and more advanced care pathways. - The mix of antibiotic resistance and chronic disease points to sustained demand for more precise treatment, not just more treatment. - North America’s lead likely reflects mature healthcare infrastructure, while Asia-Pacific’s pace signals room for faster system expansion and diagnosis uptake.
What's next: - Market growth is expected to continue as hospitals adopt more combination therapies, better pathogen testing and outpatient infusion models. - New antibiotic launches and broader access to care could strengthen the treatment market beyond 2030. - Providers and drug makers will likely keep focusing on complicated cases tied to CKD, catheter use and resistant infections.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Middle East News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.